Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Sells $185,625.00 in Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total transaction of $185,625.00. Following the sale, the chief executive officer now directly owns 440,307 shares in the company, valued at approximately $54,487,991.25. The trade was a 0.34 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Jazz Pharmaceuticals Stock Down 8.9 %

JAZZ opened at $110.04 on Friday. The stock has a market cap of $6.68 billion, a price-to-earnings ratio of 15.50, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm’s fifty day moving average is $132.27 and its 200 day moving average is $122.91. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $148.06.

Analysts Set New Price Targets

Several brokerages recently issued reports on JAZZ. HC Wainwright raised their target price on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a report on Monday, March 10th. Piper Sandler reaffirmed an “overweight” rating and issued a $176.00 price objective (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, February 26th. JPMorgan Chase & Co. increased their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Cantor Fitzgerald downgraded Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and boosted their price target for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $210.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 5th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $187.71.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of JAZZ. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Jazz Pharmaceuticals by 135.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after purchasing an additional 100,112 shares in the last quarter. Centre Asset Management LLC bought a new position in Jazz Pharmaceuticals in the 4th quarter worth approximately $9,335,000. Moloney Securities Asset Management LLC purchased a new stake in Jazz Pharmaceuticals during the 4th quarter valued at approximately $464,000. Franklin Resources Inc. raised its position in shares of Jazz Pharmaceuticals by 4.6% during the third quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock valued at $124,208,000 after buying an additional 48,708 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 13.7% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 35,894 shares of the specialty pharmaceutical company’s stock worth $4,420,000 after buying an additional 4,332 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.